| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
11,447,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
23,616 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.000001 - $0.008 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Anthera Pharmaceuticals is a biopharmaceutical company focused on advancing the development and commercialization of medicines that benefit patients with medical needs. Co. has two compounds in development, Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy intended for the treatment of patients with Exocrine Pancreatic Insufficiency, often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Truex Paul F |
President and CEO |
• • – |
2010-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
29,286 |
693,253 |
|
- |
|
| Odink Debra |
VP, Pharmaceutical R&D |
• – – |
2010-03-04 |
4 |
A |
$0.00 |
$0 |
I/I |
17,523 |
95,928 |
|
- |
|
| Leheny A. Rachel |
Director |
– • – |
2010-03-04 |
4 |
A |
$6.58 |
$2,577,332 |
I/I |
381,120 |
1,173,896 |
|
- |
|
| Leheny A. Rachel |
Director |
– • – |
2010-03-04 |
4 |
D |
$7.00 |
$161,147 |
I/I |
(23,021) |
1,008,271 |
|
- |
|
| Leheny A. Rachel |
Director |
– • – |
2010-03-04 |
4 |
OE |
$1.34 |
$161,146 |
I/I |
120,258 |
1,031,292 |
|
- |
|
| Leheny A. Rachel |
Director |
– • – |
2010-03-04 |
4 |
A |
$0.00 |
$1,185,875 |
I/I |
695,539 |
695,539 |
|
- |
|
| Fritsch Ursula |
VP, Glob. Reg. & Compliance |
• – – |
2010-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
17,523 |
73,115 |
|
- |
|
| Trias Joaquim |
SR VP, Preclinical Development |
• – – |
2010-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
17,523 |
174,166 |
|
- |
|
| Lowe Christopher P. |
CFO & VP of Administration |
• – – |
2010-03-04 |
4 |
A |
$0.00 |
$0 |
I/I |
80,997 |
98,520 |
|
- |
|
| Lowe Christopher P. |
CFO & VP of Administration |
• – – |
2010-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
17,523 |
17,523 |
|
- |
|
| Henney Christopher S |
Director |
– • – |
2010-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
46,940 |
61,542 |
|
- |
|
| Truex Paul F |
President and CEO |
• • – |
2010-03-01 |
4 |
B |
$7.05 |
$7,117 |
D/D |
1,000 |
663,967 |
2.81 |
- |
|
| Trias Joaquim |
SR VP, Preclinical Development |
• – – |
2010-02-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
156,643 |
|
- |
|
| Henney Christopher S |
Director |
– • – |
2010-02-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
14,602 |
|
- |
|
| Truex Paul F |
President and CEOOfficer |
• • – |
2010-02-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
662,967 |
|
- |
|
| Odink Debra |
VP, Pharmaceutical R&DOfficer |
• – – |
2010-02-23 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
78,405 |
|
- |
|
| Healy James |
Director |
– • – |
2010-02-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20,443 |
|
- |
|
| Fritsch Ursula |
VP, Glob. Reg. and ComplianceO |
• – – |
2010-02-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
55,592 |
|
- |
|
| Thompson David E. |
Director |
– • – |
2010-02-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20,443 |
|
- |
|
| Pennington James E |
Chief Medical Officer & Ex. VP |
• – – |
2010-02-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
105,140 |
|
- |
|
| Hislop Colin |
Sr. VP, Cardiovasc. Prod.Offic |
• – – |
2010-02-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,841 |
|
- |
|
221 Records found
|
|
Page 9 of 9 |
|
|
